Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 2/20 | 0.47 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.47 |
| ▸ | MEN1 | O00255 | 1/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.45 |
| ▸ | TSHR | P16473 | 1/20 | 0.45 |
| ▸ | THRB | P10828 | 1/20 | 0.45 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.44 |
| ▸ | CASP6 | P55212 | 2/20 | 0.43 |
| ▸ | POLB | P06746 | 2/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.41 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.40 |
| ▸ | PDE3B | Q13370 | 1/20 | 0.39 |
| ▸ | PDE3A | Q14432 | 1/20 | 0.39 |
| ▸ | GAA | P10253 | 1/20 | 0.38 |
| ▸ | HTT | P42858 | 1/20 | 0.38 |
| ▸ | SCN5A | Q14524 | 1/20 | 0.38 |
| ▸ | SCN2A | Q99250 | 1/20 | 0.38 |
| ▸ | SCN10A | Q9Y5Y9 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL991535 | 0.88 | TDP1 (0.55) | KMT2ATDP1MEN1CASP6POLB | |
| SCHEMBL12950492 | 0.84 | THRB (0.44) | KMT2ATDP1ALDH1A1TSHRTHRB | |
| SCHEMBL992135 | 0.83 | POLB (0.61) | KMT2ATDP1MEN1ALDH1A1KDM4E | |
| SCHEMBL1079065 | 0.81 | ALDH1A1 (0.57) | KMT2ATDP1MEN1ALDH1A1TSHR | |
| SCHEMBL11980693 | 0.81 | TDP1 (0.57) | KMT2ATDP1ALDH1A1TSHRTHRB | |
| SCHEMBL19442012 | 0.80 | KDM4E (0.50) | KMT2ATDP1ALDH1A1TSHRTHRB | |
| SCHEMBL991053 | 0.78 | KMT2A (0.51) | KMT2ATDP1MEN1ALDH1A1 | |
| SCHEMBL992517 | 0.77 | LMNA (0.54) | KMT2ATDP1MEN1ALDH1A1TSHR | |
| SCHEMBL991587 | 0.76 | ALDH1A1 (0.52) | KMT2ATDP1MEN1ALDH1A1TSHR | |
| SCHEMBL14857328 | 0.75 | KDM4E (0.41) | KMT2AALDH1A1TSHRTHRBKDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 23 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9782382-B2 | TOFA analogs useful in treating dermatological disorders or conditions | DERMIRA (CANADA), INC. (US) | 2017-10-10 | — | — | US | claimed |
| US-20160338988-A1 | TOFA ANALOGS USEFUL IN TREATING DERMATOLOGICAL DISORDERS OR CONDITIONS | DERMIRA (CANADA) INC (US) | 2016-11-24 | — | — | US | claimed |
| EP-2641906-B1 | Tofa analogs useful in treating dermatological disorders or conditions | DERMIRA CANADA INC (US) | 2015-04-22 | — | — | EP | claimed |
| US-8884034-B2 | TOFA analogs useful in treating dermatological disorders or conditions | DERMIRA (CANADA), INC. (US) | 2014-11-11 | — | — | US | claimed |
| EP-2641906-A1 | Tofa analogs useful in treating dermatological disorders or conditions | Dermira (Canada), Inc. (US) | 2013-09-25 | — | — | EP | claimed |
| EP-2451796-B1 | TOFA ANALOGS USEFUL IN TREATING DERMATOLOGICAL DISORDERS OR CONDITIONS | DERMIRA CANADA INC (US) | 2013-04-17 | — | — | EP | claimed |
| US-20120208807-A1 | TOFA ANALOGS USEFUL IN TREATING DERMATOLOGICAL DISORDERS OR CONDITIONS | Valocor Therapeutics, Inc. (CA) | 2012-08-16 | — | — | US | claimed |
| EP-2451796-A1 | TOFA ANALOGS USEFUL IN TREATING DERMATOLOGICAL DISORDERS OR CONDITIONS | Dermira (Canada), Inc. (CA) | 2012-05-16 | — | — | EP | claimed |
| WO-2011005660-A1 | TOFA ANALOGS USEFUL IN TREATING DERMATOLOGICAL DISORDERS OR CONDITIONS | Valocor Therapeutics, Inc. (CA) | 2011-01-13 | — | — | WO | claimed |
| US-20260034091-A1 | Compositions and Methods for Treating Metabolic Disorders | UNIV CALIFORNIA (US) | 2026-02-05 | — | — | US | disclosed |
| EP-4561557-A1 | COMPOSITIONS AND METHODS FOR TREATING METABOLIC DISORDERS | The Regents of the University of California (US) | 2025-06-04 | — | — | EP | disclosed |
| WO-2024026012-A1 | COMPOSITIONS AND METHODS FOR TREATING METABOLIC DISORDERS | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2024-02-01 | — | — | WO | disclosed |
| US-9782382-B2 | TOFA analogs useful in treating dermatological disorders or conditions | DERMIRA (CANADA), INC. (US) | 2017-10-10 | — | — | US | disclosed |
| US-20160338988-A1 | TOFA ANALOGS USEFUL IN TREATING DERMATOLOGICAL DISORDERS OR CONDITIONS | DERMIRA (CANADA) INC (US) | 2016-11-24 | — | — | US | disclosed |
| US-8884034-B2 | TOFA analogs useful in treating dermatological disorders or conditions | DERMIRA (CANADA), INC. (US) | 2014-11-11 | — | — | US | disclosed |
| EP-2641906-A1 | Tofa analogs useful in treating dermatological disorders or conditions | Dermira (Canada), Inc. (US) | 2013-09-25 | — | — | EP | disclosed |
| EP-2451796-B1 | TOFA ANALOGS USEFUL IN TREATING DERMATOLOGICAL DISORDERS OR CONDITIONS | DERMIRA CANADA INC (US) | 2013-04-17 | — | — | EP | disclosed |
| US-20120208807-A1 | TOFA ANALOGS USEFUL IN TREATING DERMATOLOGICAL DISORDERS OR CONDITIONS | Valocor Therapeutics, Inc. (CA) | 2012-08-16 | — | — | US | disclosed |
| EP-2451796-A1 | TOFA ANALOGS USEFUL IN TREATING DERMATOLOGICAL DISORDERS OR CONDITIONS | Dermira (Canada), Inc. (CA) | 2012-05-16 | — | — | EP | disclosed |
| WO-2011005660-A1 | TOFA ANALOGS USEFUL IN TREATING DERMATOLOGICAL DISORDERS OR CONDITIONS | Valocor Therapeutics, Inc. (CA) | 2011-01-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160338988-A1 | TOFA ANALOGS USEFUL IN TREATING DERMATOLOGICAL DISORDERS OR CONDITIONS | FAH, CUTA, ALOX5AP | KMT2A 2716/4885TDP1 3363/4885MEN1 4056/4885 |
| US-20120208807-A1 | TOFA ANALOGS USEFUL IN TREATING DERMATOLOGICAL DISORDERS OR CONDITIONS | FAH, CUTA, ALOX5AP | KMT2A 3026/4885TDP1 3323/4885MEN1 3929/4885 |
| US-20260034091-A1 | Compositions and Methods for Treating Metabolic Disorders | LIPC, GPR119, PNLIP | KMT2A 3144/4885TDP1 4755/4885MEN1 3713/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.